Literature DB >> 17475971

Imaging hNET reporter gene expression with 124I-MIBG.

Maxim A Moroz1, Inna Serganova, Pat Zanzonico, Ludmila Ageyeva, Tatiana Beresten, Ekaterina Dyomina, Eva Burnazi, Ronald D Finn, Michael Doubrovin, Ronald G Blasberg.   

Abstract

UNLABELLED: The norepinephrine transporter (NET) has recently been suggested as a useful reporter gene. We have extended this effort by constructing an internal ribosomal entry site (IRES)-linked hNET-green fluorescent protein (GFP) hybrid reporter gene for both nuclear and optical imaging.
METHODS: A retroviral vector pQCXhNET-IRES-GFP was constructed and used to generate several reporter cell lines and xenografts. Transduced cells were sorted by fluorescence-activated cell sorting based on GFP expression and used for both in vitro and in vivo imaging studies.
RESULTS: The transduced reporter cells accumulated (123)I- or (124)I-labeled metaiodobenzylguanidine (MIBG) to high levels compared with the wild-type parent cell lines. Differences in MIBG accumulation between cell lines were primarily due to differences in influx (K(1)) rather than efflux (k(2)). The estimated MIBG distribution volumes (V(d)) for transduced Jurkat, C6, and COS-7 cells were 572 +/- 13, 754 +/- 25, and 1,556 +/- 38 mL/g, respectively. A correlation between radiotracer accumulation (K(1)) and GFP fluorescence intensity was also demonstrated. Sequential imaging studies of mice bearing pQCXhNET-IRES-GFP transduced and wild-type C6 xenografts demonstrated several advantages of (124)I-MIBG small-animal PET compared with (123)I-MIBG gamma-camera/SPECT. This was primarily due to the longer half-life of (124)I and to the retention and slow clearance (half-time, 63 +/- 6 h) of MIBG from transduced xenografts compared with that from wild-type xenografts (half-time, 12 +/- 1 h) and other organs (half-time, 2.6-21 h). Very high radioactivity ratios were observed at later imaging times; at 73 h after (124)I-MIBG injection, the C6/hNET-IRES-GFP xenograft-to-muscle ratio was 293 +/- 48 whereas the C6 xenograft-to-muscle ratio was 0.71 +/- 0.19.
CONCLUSION: These studies demonstrate the potential for a wider application of hNET reporter imaging and the future translation to patient studies using radiopharmaceuticals that are currently available for both SPECT and PET.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475971     DOI: 10.2967/jnumed.106.037812

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  45 in total

1.  A practical, automated synthesis of meta-[(18)F]fluorobenzylguanidine for clinical use.

Authors:  Bao Hu; Amy L Vāvere; Kiel D Neumann; Barry L Shulkin; Stephen G DiMagno; Scott E Snyder
Journal:  ACS Chem Neurosci       Date:  2015-09-11       Impact factor: 4.418

2.  Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.

Authors:  Hanwen Zhang; Ruimin Huang; NagaVaraKishore Pillarsetty; Daniel L J Thorek; Ganesan Vaidyanathan; Inna Serganova; Ronald G Blasberg; Jason S Lewis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-31       Impact factor: 9.236

Review 3.  PET molecular imaging in stem cell therapy for neurological diseases.

Authors:  Jiachuan Wang; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-23       Impact factor: 9.236

4.  Radiolabeling strategies for radionuclide imaging of stem cells.

Authors:  Esther Wolfs; Catherine M Verfaillie; Koen Van Laere; Christophe M Deroose
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

Review 5.  Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.

Authors:  Youngho Seo
Journal:  Nucl Med Mol Imaging       Date:  2019-02-18

Review 6.  Genetic engineered molecular imaging probes for applications in cell therapy: emphasis on MRI approach.

Authors:  In K Cho; Silun Wang; Hui Mao; Anthony Ws Chan
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-09-22

7.  Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models.

Authors:  Ian R Marsh; Joseph Grudzinski; Dana C Baiu; Abigail Besemer; Reinier Hernandez; Justin J Jeffery; Jamey P Weichert; Mario Otto; Bryan P Bednarz
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

Review 8.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

Review 9.  Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

Authors:  K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

10.  A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging.

Authors:  Nanhai Chen; Qian Zhang; Yong A Yu; Jochen Stritzker; Peter Brader; Andreas Schirbel; Samuel Samnick; Inna Serganova; Ronald Blasberg; Yuman Fong; Aladar A Szalay
Journal:  Mol Med       Date:  2009-02-25       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.